Top

Cancer Causes & Control

Published in:

01-02-2007 | Original Paper

Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States)

Authors: Wade T. Barranco, Paul F. Hudak, Curtis D. Eckhert

Published in: Cancer Causes & Control | Issue 1/2007

Abstract

Objective

To determine: (1) the correlation of prostate cancer incidence and mortality with groundwater boron and selenium concentrations; and (2) the impact of boron on prostate cancer cell proliferation during co-treatment with alternative chemo-preventative agents, along with boron pre-treatment effects on cell sensitivity to ionizing radiation.

Methods

For regression analysis, data on prostate cancer incidence and mortality were obtained from the Texas Cancer Registry, while groundwater boron and selenium concentrations were derived from the Texas Water Development Board. Cultured DU-145 prostate cancer cells were used to assess the impact of boric acid on cell proliferation when applied in combination with selenomethionine and genistein, or preceding radiation exposure.

Results

Groundwater boron levels correlated with a decrease in prostate cancer incidence (R = 0.6) and mortality (R = 0.6) in state planning regions, whereas selenium did not (R = 0.1; R = 0.2). Growth inhibition was greater during combined treatments of boric acid and selenomethionine, or boric acid and genistein, versus singular treatments. 8-day boric acid pre-exposure enhanced the toxicity of ionizing radiation treatment, while dose-dependently decreasing the expression of anti-apoptotic protein Bcl-2.

Conclusions

Increased groundwater boron concentrations, across the state of Texas, correlate with reduced risk of prostate cancer incidence and mortality. Also, boric acid improves the anti-proliferative effectiveness of chemo-preventative agents, selenomethionine and genistein, while enhancing ionizing radiation cell kill.

Jemal A, Murray T, Ward E, et al (2005). Cancer statistics. CA Cancer J Clin 55(1):10–30PubMedCrossRef

Willis MS, Wians FH (2004) The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clinica Chimica Acta 330: 57–83CrossRef

Djavan B, Zlotta A, Schulman C, et al (2004) Chemotherapeutic prevention studies of prostate cancer. J Urol 171(2 Pt 2): S10–S13PubMedCrossRef

Klein EA, Thompson IM, Lippman SM, et al (2001) SELECT: the next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 166(4): 1311–1315 PubMedCrossRef

http://www.clinicaltrials.gov

Cui Y, Winton MI, Zhang ZF, et al (2004) Dietary boron intake and prostate cancer risk. Oncol Rep 11(4): 887–892PubMed

Gallardo-Williams MT, Chapin RE, King PE, et al (2004) Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicol Pathol 32: 73–78PubMedCrossRef

Gallardo-Williams MT, Maronpot RR, Wine RN, Brunssen SH, Chapin RE (2003) Inhibition of the enzymatic activity of prostate specific antigen by BA and 3-nitrophenyl boronic acid. Prostate 54: 44–49PubMedCrossRef

Barranco WT, Eckhert CD (2004) BA inhibits human prostate cancer cell proliferation. Cancer Lett 216(1): 21–9PubMedCrossRef

10.

Kobayashi M, Matoh T, Azuma J (1996) Two chains of rhamnogalacturonan II are cross-linked by borate-diol ester bonds in higher plant cell walls. Plant Physiol 110(3): 1017–1020PubMed

11.

O’Neill MA, Warrenfeltz D, Kates K, et al (1997) Rhamnogalacturonan-II, a pectic polysaccharide in the walls of growing plant cell, forms a dimer that is covalently cross-linked by a borate ester. In vitro conditions for the formation and hydrolysis of the dimer. J Biol Chem 271(37): 22923–22930

12.

Takano J, Noguchi K, Yasumori M, et al (2002) Arabidopsis boron transporter for xylem loading. Nature 420(6913): 337–340PubMedCrossRef

13.

Anderson DL, Cunningham WC, Lindstrom TR (1994) Concentrations and intakes of H, B, S, K Na, Cl, and NaCl in foods. J Food Comp Anal 7: 59–82CrossRef

14.

Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. A report of the panel on micronutrients, subcommittees on upper reference levels of nutrients and of interpretation and use of dietary reference intakes, and the standing committee on the scientific Evaluation of dietary reference Intakes. (2001) Food and Nutrition Board, Institute of Medicine, National Academy Press, Washington, D.C., p C-13

15.

Hudak PF (2004) Boron and selenium contamination in south Texas groundwater. J Environ Sci Health A Tox Hazard Subst Environ Eng 39(11–12):2827–2834PubMedCrossRef

16.

Hem JD (1985) Study and interpretation of the chemical characteristics of natural water. U.S. Geological Survey Water Supply Paper 2254

17.

http://www.tcc.state.tx.us/tcplan/goal2/goal2_obje_frames.html

18.

http://www.dshs.state.tx.us/tcr, accessed May 31, 2005

19.

http://www.twdb.state.tx.us, accessed May 31, 2005

20.

Panel on Dietary Reference Intakes for Electrolytes and Water (2004) Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. National Academies Press, Washington, D.C., p 494.

21.

Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids (2000) Selenium. National Academies Press, Washington, D.C., p. 284.

22.

Clark LC, Dalkin B, Krongrad A, et al (1998) Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 81: 730–734PubMed

23.

Eckhert CD, Lockwood MK, Shen B (1993) Influence of selenium on the microvascular circulation of the retina. Microvas Res 45: 74–82CrossRef

24.

Thornber JM, Eckhert CD (1984) Protection against sucrose induced retinal capillary damage in the Wistar rat. J Nutr 114:1070−1075PubMed

25.

Bischof M, Abdollahi A, Gong P, et al (2004) Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 60(4):1220–1232PubMedCrossRef

26.

Yan SX, Ejima Y, Sasaki R, et al (2004) Combination of genistein with ionizing radiation on androgen-independent prostate cancer cells. Asian J Androl 6(4): 285–290PubMed

27.

Husbeck B, Peehl DM, Knox SJ (2005) Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med 38(1):50–57PubMedCrossRef

28.

Bendel P (2005) Biomedical applications of 10B and 11B NMR. NMR Biomed 18(2): 74–82PubMedCrossRef

29.

Rudner J, Jendrossek V, Belka C (2002) New insights in the role of Bcl-2 Bcl-2 and the endoplasmic reticulum. Apoptosis 7(5): 441–447PubMedCrossRef

30.

Rosser CJ, Reyes AO, Vakar-Lopez F et al (2003) Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys 56(1): 1–6PubMedCrossRef

31.

Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM (2004) Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene 23(8): 1599–1607PubMedCrossRef

32.

Campbell MJ, Dawson M, Koeffler HP (1998) Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl) all-trans retinamide. Br J Cancer 77(5): 739–744PubMed

33.

Raffo A, Lai JC, Stein CA, et al (2004) Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res May 10(9): 3195–3206CrossRef

Title: Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States)
Authors: Wade T. Barranco
Paul F. Hudak
Curtis D. Eckhert
Publication date: 01-02-2007
Publisher: Kluwer Academic Publishers
Published in: Cancer Causes & Control / Issue 1/2007
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-006-0077-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2007

Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study

An evaluation of spatial and multivariate covariance among childhood cancer histotypes in Texas (United States)

Manganese superoxide dismutase polymorphism and risk of skin cancer (United States)

Wine and other alcohol consumption and risk of ovarian cancer in the California Teachers Study cohort

Which women aren’t getting mammograms and why? (United States)

Transient caloric restriction and cancer risk (The Netherlands)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer